Cancer Treatment Cost in China: What Is Published, What Is a Flyer
There is no single China cancer treatment cost. SPHIC has published RMB 278,000 for a particle course (typical inpatient totals around RMB 330,000). Blood-cancer CAR-T navigator bands often sit in the mid five-figure USD range; private packages often about USD 70,000-90,000. We itemise drivers after pathology. About 24 hours. No obligation to book.
Average reply: 24 hoursNo obligation to book
No single pricedrivers after slides
RMB 278k beamSPHIC published
CAR-T bandsnot our invoice
Quick answer
There is no single “China cancer treatment cost.” Surgery, drugs, CAR-T, proton and a private ablation package are different invoices. Public particle therapy at SPHIC has a published course fee of RMB 278,000 (typical inpatient totals around RMB 330,000). Blood-cancer CAR-T navigator bands often sit in the mid five-figure USD range at selected public rooms, with private packages often about USD 70,000-90,000. Satri-cel cellular product has been cited around RMB 990,000 before stay and toxicity care. We itemise drivers after pathology. About 24 hours. No obligation to book.
What the papers and hospital notices say
SPHIC has published a flat particle-course price. NMPA labels tell you whether a cell product is even legal for the histology. Satri-cel’s Lancet phase 2 showed a 1.48-month median PFS gain with very high grade ≥3 adverse-event rates — ICU days change any quote. Drug bills (TKIs, ADCs, checkpoint inhibitors) usually outrun the operation in metastatic disease.
Eight lines that actually move the bill
The clinical hub lists methods. This page lists money. If a quote is silent on these lines, it is not comparable.
Oncology Drug Pricing in China
Oncology drug pricing in China varies by the exact medicine, approved indication, dose, treatment cycle, hospital procurement, insurance eligibility and whether the treatment is standard care or part of a clinical trial. Imported drugs and Chinese-developed oncology drugs may follow different pricing and reimbursement pathways. A reliable estimate therefore requires the exact drug name, dose schedule and hospital plan rather than a generic “cancer drug price.”
For targeted therapy, immunotherapy, CAR-T cell therapy or other high-cost treatments, ask the hospital for a written estimate that separates the drug itself from diagnostics, hospitalization, procedures, supportive care and international-service fees.
1. Protocol, not ‘cancer’
Surgery vs systemic drugs vs proton vs CAR-T vs satri-cel. Mixed into one word, the number is fiction.
2. Public vs private track
The low public CAR-T band is real for some files and closed for others. English desk and slot speed cost money on the private side.
3. Product vs professional fees
Satri-cel’s cited RMB 990,000 is the cell product. Admission, lymphodepletion and CRS care sit next to it.
4. Planned bed days
A two-week brochure dies when monitoring needs four. Ask the per-day rate after the package week.
5. ICU and toxicity rule
CAR-T without a written CRS/ICU policy is not a quote. Proton without a plan for interruption is not a calendar.
6. Drugs inside vs extra
Targeted agents and supportive meds often leak. Demand names, not ‘medicines included’.
7. Extra imaging and labs
Restaging PET, molecular repeats, and planning CT are frequent add-ons — especially if you arrive with incomplete DICOM.
8. Housing and a second adult
Proton is weeks of hotel. CAR-T needs a companion near the ward. These rarely sit on the medical PDF.
Indicative bands (same numbers as the clinical pages)
Planning figures from public navigation sources. Not an invoice. Confirm with the treating centre after records.
| Pathway | Planning range | Must appear on the letter |
|---|---|---|
| Selected public-hospital CAR-T (blood cancers) | from about USD 25,000 | product name, slot timing, English desk, ICU rule |
| Private-hospital CAR-T (blood cancers) | about USD 70,000-90,000 | what extra cycles and CRS days cost |
| Satri-cel cellular product only | about RMB 990,000 / USD 146,000 | product vs admission vs lymphodepletion vs toxicity |
| Complex commercial CAR-T packages | up to about USD 170,000-200,000 | whether transplant or long isolation is inside |
| Proton course | about USD 20,000-35,000 | fraction count, extra imaging, hotel weeks |
| Surgery + systemic solid-tumour care | no honest single band | operation, drugs by name, planned days, restaging |
Checklist before you treat two PDFs as rivals
Same diagnosis, stage and line of therapy
Approved vs trial labelled in writing
Product / protocol name, not ‘immunotherapy’
Bed days + post-package daily rate
ICU / CRS / infection policy
Deposit, refund, and what currency you pay
Cancer hub · CAR-T eligibility · Proton calendar · Which hospital
What actually changes the plan
📋
Same diagnosis, same basket
We will not compare a public CAR-T screen with a two-week Guangzhou brochure. The file defines the basket first.
🏥
Itemised hospital letter
Product or protocol, planned days, ICU rule, drugs in/out, deposit. If a line is missing, the number is not usable.
✈️
Stay and companion costs
Hotel weeks (especially proton), interpreter, a second adult, and what happens if discharge slips. These sit outside most medical quotes.
What this page helps you decide
✅
Drivers before a teaser price
We list what moves the bill so a USD 18k screenshot cannot masquerade as CAR-T.
💬
Public vs private labelled
The cheaper public band is narrower on slots and English. We say so before you chase it.
🌍
Same bands as the clinical pages
CAR-T, satri-cel and proton figures here match the treatment pages. We do not run two price stories.
Evidence table
Published SPHIC fee, navigator CAR-T bands, satri-cel product cite, toxicity as a cost driver.
| Source | What it says | Relevance to patients |
|---|---|---|
| SPHIC / municipal press (2015-) | RMB 278,000 particle course; ~RMB 330,000 inpatient | Published beam fee, not a cancer-wide price. |
| Navigator CAR-T bands (current) | Public mid five-figure USD; private often ~70-90k | Marketing bands until a centre writes an estimate. |
| Satri-cel product cites (2026) | ~RMB 990,000 cellular product before admission | Plus lymphodepletion, CRS watch, ICU. |
| Lancet satri-cel (2025-26) | PFS 3.25 vs 1.77 months; G≥3 AE 99% | Toxicity is a cost driver, not a footnote. |
Who this page is for
Families with a US or EU bill in hand
Need a China comparison that uses the same protocol, not a cheaper unrelated package.
Patients shopping CAR-T or satri-cel
Need product-only vs all-in numbers and the list of exclusions before they wire a deposit.
Patients who were sent a 'China cancer package'
Need someone to say what that PDF actually covers — and what it silently drops.
What you can actually book
A written driver list after slides and staging: which basket (surgery / systemic / particle / labelled cell / trial / none), which centre class, what is included, what blows the total. Related: cancer hub, CAR-T, proton.
What moves the cost
Cost-driver review
No charge to start
Pathway label • Planning band • What a letter must itemise • Red flags on brochure packages
Quote coordination
After a centre sees the file
Hospital estimate chase • Inclusion check • Public vs private split • Visa/stay cost notes
These are routing steps, not a hospital package SKU. Published procedure examples stay in the evidence/cost sections only when a source exists. Hospital, drugs, stay, interpreter and travel are quoted separately after records.
What happens next
01
Send the file, not a target budget only
Pathology, imaging, prior lines and drugs. A budget without a protocol produces a fantasy range.
02
Label the pathway
Standard multimodal, approved CAR-T, satri-cel screen, proton, or trial. Each has a different cost shape.
03
Read the hospital letter line by line
We mark inclusions, exclusions and open risks (ICU, extra cycles) before anyone pays a deposit.
Request a preliminary case review
Tell us the basics of your case. When you submit, WhatsApp will open with the information you entered so you can review it before sending. This is a preliminary routing request, not a diagnosis, treatment acceptance, trial enrollment, visa decision, or medical advice.
Frequently asked questions
How much is cancer treatment in China?
It depends on the basket. SPHIC particle course RMB 278,000 published. Public CAR-T sometimes mid five-figure USD; private often about USD 70,000-90,000. Satri-cel product cited around RMB 990,000 before stay and ICU. Surgery-plus-drugs is a different invoice.
Is there an all-inclusive package?
Ads say so. Drugs, ICU, extra fractions and interpreter weeks usually sit outside. Ask what is excluded.
Why can CAR-T cost more than surgery?
Manufacturing, lymphodepletion, CRS watch and ICU days. Lancet satri-cel: grade 3 or higher adverse events in 99% of the treated arm.
Do you give a USD number before slides?
No. A number before histology is marketing.
Is proton cheaper than in the US?
SPHIC's published fee is typically mid five-figure USD; US cash-pay proton is often six figures. Indication still has to fit.
What records should I send?
Pathology, staging, prior lines, the quote you were shown.
Who invoices me?
The hospital, not Parkmega. We are a matching service.
Do you lock a price on the website?
No. Average reply about 24 hours. No obligation to book.
Do I pay before you read the file?
No. Payment required before a file review is a red flag. Average reply about 24 hours. No obligation to book.
How fast do you reply?
About 24 hours. We label the file as labelled care, trial, or marketing. No obligation to book.
Red flags in offers
One USD number for “cancer in China.” That number usually hides drugs, ICU, extra fractions, interpreter weeks and whether the indication is labelled. Fuda-style ablation quotes are not interchangeable with a public MDT estimate.
A single USD price before histology.
Deposit equal to the full package before records.
“All inclusive” that excludes drugs, ICU and extra nights.
CAR-T or proton quoted for an unlabelled indication.
Sources
SPHIC published particle-course fee (RMB 278,000) and municipal inpatient totals (~RMB 330,000).
NMPA labels for CD19/BCMA CAR-T and satri-cel (22 June 2026).
Lancet satri-cel phase 2 toxicity as a cost warning.
Public navigator bands for CAR-T packages — labelled as navigator, not our invoice.
This page is a matching note, not a bill.
Freshness label on this page: 2026-08-15